Colorectal cancer

  title={Colorectal cancer},
  author={David Cunningham and Wendy S. Atkin and Heinz-Josef Lenz and Henry T. Lynch and Bruce D. Minsky and Bernard Nordlinger and Naureen Starling},
  journal={The Lancet},

Figures and Tables from this paper

Improving outcomes in colorectal cancer: where do we go from here?
Microsatellite instability & survival in patients with stage II/III colorectal carcinoma
MSI-H CRCs had a lower recurrence rate, but the prognosis was worse following adjuvant 5-FU therapy, and multi- and univariate Cox regression analysis failed to show a difference between MSI-H and MSS groups with respect to disease-free, disease-specific and overall survival.
Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm
The current multidisciplinary context in which LARC care should be delivered is outlined and how some key prognosticators, including novel histopathological, molecular genetics, and immunological biomarkers might fit into the wider context of personalized LARC management in the coming years are discussed.
Managing advanced colorectal cancer: have we reached the PEAK with current therapies?
  • B. Wolpin, A. Bass
  • Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
The primary result of this trial does not suggest a difference in controlling disease progression for one regimen versus the other in the primary analysis population, and further results of interest are provided in secondary analyses.
Personalisation of therapy in advanced colorectal cancer
Further clinical and molecular biomarkers have shown potential clinical utility in aCRC, which all hold promise for routine application and to further personalise treatment in aRAS-wt patients.
Risk Factors of Tumour Recurrence and Reduced Survival in Rectal Cancer
Analysis of potential risk factors of tumour recurrence and reduced survival in a cohort of patients registered in the SRCR between 1995 and 1997 with 5-year follow-up in Sweden suggests high immunohistochemical expression of the tumour marker ezrin in primary tumours from patients with LR correlated to earlier occurrence of LR.
Genetic Heterogeneity in Colorectal Cancer and its Clinical Implications.
The widespread use of next-generation sequencing techniques will allow a better understanding of the true degree of genetic heterogeneity in colorectal tumours, its causes and impact on the course of the disease.
Changing concepts and trends in rectal cancer patients
MR based TA of rectal cancers can predict outcome before undergoing surgery and could potentially select patients with predicted poor prognosis for personalized intensive therapy.
Environmental Exposures, Tumor Heterogeneity, and Colorectal Cancer Outcomes
Using the KRAS mutation as a predictive biomarker for anti-epidermal growth factor receptor therapy is an example of how the genetic diversity of tumors can lead to a more individual or so-called personalized medicine with the goal of providing more benefits to patients, without unnecessary adverse side effects.
Metastatic Colorectal Cancer and the Need for More Endoscopic Tools
A 48-year-old man with stage IVB sigmoid adenocarcinoma diagnosed in 2007 treated with five different lines of adjuvant chemotherapy, right lobectomy for liver metastasis, and video-assisted thoracoscopy for pulmonary metastasis presenting with jaundice and abdominal pain survived 7 years from his initial diagnosis of stage IV colorectal cancer with endoscopic and oncologic management.


Actual 10-year survival after resection of colorectal liver metastases defines cure.
In well-selected patients, there is at least a one in six chance of cure after hepatectomy for CLM, and the presence of poor prognostic factors does not preclude the possibility of long-term survival and cure.
Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer.
Compared to preoperative RT alone, preoperative CRT enhances pathological response and improves local control in resectable stage II and III rectal cancer, but does not benefit disease free or overall survival.
Clinical management of hereditary colorectal cancer syndromes
The management of the inherited colorectal cancer syndromes has progressed substantially over the past years because of advancement of genetic understanding and testing options, which have led to the possibility of preclinical diagnosis and early surveillance and treatment.
Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: The EUROCARE study
There is a huge potential for reducing the burden of CRC in Europe by more widespread and equal delivery of existing options of effective early detection and curative treatment to the European population.
Complete response of colorectal liver metastases after chemotherapy: does it mean cure?
Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome
Routine use of MSI testing may be considered in colorectal cancer patients up to the age of 70 years, with a central role for the pathologist in the selection of patients.
Molecular tests for colorectal cancer screening.
An overview of the performances of DNA, RNA, and protein markers for CRC detection in stool and blood is provided and the recent boost in proteomics research leads to many new candidate protein markers.
A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy.
Factors that are associated most strongly with risk of advanced neoplasia are patient age and the number and size of prior adenomas.
Circumferential Margin Involvement Is Still an Important Predictor of Local Recurrence in Rectal Carcinoma: Not One Millimeter but Two Millimeters Is the Limit
This study analyzes the criteria by which the CRM needs to be assessed to predict local recurrence for nonirradiated patients and shows that an increased risk is present when margins are ≤2 mm, compared with earlier studies.